AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12086380 — intervention group
Group type: EXPERIMENTAL
Intervention: Terminalia arjuna (500 mg 8 hourly)
Number of subjects: 58
Study 12086380 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (40 mg/daily)
Number of subjects: 58
Study 12086380 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 9695894 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic therapy (theophylline, inhaled bronchodilators, steroids, antianxiolytics, antidepressants)
Number of subjects: 0
Study 9695894 — intervention group
Group type: EXPERIMENTAL
Intervention: General exercise strategies (exercise training, exercise and comprehensive pulmonary rehabilitation, upper extremity training)
Number of subjects: 0
Study 9695894 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle therapy (inspiratory muscle training, inspiratory muscle rest)
Number of subjects: 0
Study 9695894 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional therapy
Number of subjects: 0
Study 9695894 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 0
Study 9695894 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized nursing care
Number of subjects: 0
Study 7888387 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniospinal irradiation and chemotherapy
Number of subjects: 27
Study 2171446 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum plus citrate (as Shohl's solution)
Number of subjects: 8
Study 2171446 — intervention group
Group type: COMPARATOR
Intervention: Aluminum alone
Number of subjects: 8
Study 2171446 — intervention group
Group type: COMPARATOR
Intervention: Aluminum plus sodium bicarbonate
Number of subjects: 8
Study 2171446 — intervention group
Group type: COMPARATOR
Intervention: Citrate alone
Number of subjects: 8
Study 622844 — intervention group
Group type: EXPERIMENTAL
Intervention: Ajmaline (50 mg)
Number of subjects: 10
Study 622844 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (100 mg)
Number of subjects: 10
Study 31195857 — intervention group
Group type: EXPERIMENTAL
Intervention: BM-PHA
Number of subjects: 91
Study 31195857 — intervention group
Group type: COMPARATOR
Intervention: Restylane Perlane (PER)
Number of subjects: 91
Study 30051255 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health application for recruitment
Number of subjects: 0
Study 29262841 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 2000
Study 29262841 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 2000
Study 26427627 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 52
Study 26427627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 23327643 — intervention group
Group type: EXPERIMENTAL
Intervention: Board game intervention (Pick-Klop group)
Number of subjects: 0
Study 23327643 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation group
Number of subjects: 0
Study 23327643 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study 21278617 — intervention group
Group type: EXPERIMENTAL
Intervention: ACWY‐TT (tetravalent meningococcal conjugate vaccine)
Number of subjects: 1501
Study 21278617 — intervention group
Group type: COMPARATOR
Intervention: Men‐PS (licensed tetravalent meningococcal polysaccharide vaccine)
Number of subjects: 1501
Study 19032560 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 10 mg/ml
Number of subjects: 30
Study 19032560 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg/ml
Number of subjects: 30
Study 17156291 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV vaccine
Number of subjects: 0
Study 17156291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (rabies vaccine)
Number of subjects: 0
Study 17156291 — intervention group
Group type: COMPARATOR
Intervention: HIV vaccine (administered to placebo patients at trial closeout)
Number of subjects: 0
Study 15494897 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir at 1000 mg twice daily for 5 days
Number of subjects: 0
Study 15494897 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir at 500 mg twice daily
Number of subjects: 0
Study 11226098 — intervention group
Group type: EXPERIMENTAL
Intervention: FBM: fentanyl (25 microg) and bupivacaine (2.5 mg) plus morphine (150 microg)
Number of subjects: 95
Study 11226098 — intervention group
Group type: COMPARATOR
Intervention: FB: fentanyl (25 microg) and bupivacaine (2.5 mg)
Number of subjects: 95
Study 11154952 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO solution containing 1.7 g CHO/kg(body weight)
Number of subjects: 8
Study 11154952 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric solution containing 1.2 g CHO/kg(body weight) plus 0.5 g protein/kg(body weight) (including 5 g arginine)
Number of subjects: 8
Study 11154952 — intervention group
Group type: COMPARATOR
Intervention: Zero-caloric placebo diet
Number of subjects: 8
Study 8989740 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.58 g/kg per day)
Number of subjects: 585
Study 8989740 — intervention group
Group type: COMPARATOR
Intervention: Usual-protein diet (1.3 g/kg per day)
Number of subjects: 585
Study 1637601 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural analgesia initiated 40 min before surgical incision
Number of subjects: 32
Study 1637601 — intervention group
Group type: COMPARATOR
Intervention: Extradural analgesia initiated at closure of the surgical wound
Number of subjects: 32
Study 6721526 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment
Number of subjects: 6
Study 6721526 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 6
Study 31685813 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (50-200 mg/day)
Number of subjects: 62
Study 31685813 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 62
Study 29174422 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium screw
Number of subjects: 26
Study 29174422 — intervention group
Group type: COMPARATOR
Intervention: Titanium screw
Number of subjects: 26
Study 26733011 — intervention group
Group type: EXPERIMENTAL
Intervention: PsychoEducation, Paced Respiration, and Relaxation (PEPRR)
Number of subjects: 24
Study 26733011 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 24
Study 25227174 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction score feedback with usual multisource feedback
Number of subjects: 0
Study 25227174 — intervention group
Group type: COMPARATOR
Intervention: Usual multisource feedback alone
Number of subjects: 0
Study 22150634 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined parent and teacher manual-based group training programme (modified version of Barkley's programme)
Number of subjects: 129
Study 22150634 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 129
Study 20456211 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg q.d.
Number of subjects: 1172
Study 20456211 — intervention group
Group type: COMPARATOR
Intervention: Glipizide 5 mg/day (up-titrated to 20 mg/day)
Number of subjects: 1172
Study 17429836 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with imatinib (Ind(IM))
Number of subjects: 55
Study 17429836 — intervention group
Group type: COMPARATOR
Intervention: Induction therapy with multiagent, age-adapted chemotherapy (Ind(chemo))
Number of subjects: 55
Study 17429836 — intervention group
Group type: COMPARATOR
Intervention: Ind(chemo)
Number of subjects: 55
Study 17429836 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined imatinib and chemotherapy consolidation
Number of subjects: 55
Study 17429836 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 55
Study 16338283 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (1.5-600 mg)
Number of subjects: 0
Study 16338283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12033714 — intervention group
Group type: EXPERIMENTAL
Intervention: Asperger syndrome
Number of subjects: 150
Study 12033714 — intervention group
Group type: COMPARATOR
Intervention: Autistic disorder
Number of subjects: 150
Study 12033714 — intervention group
Group type: COMPARATOR
Intervention: ADHD
Number of subjects: 150
Study 9807990 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA users
Number of subjects: 29
Study 9807990 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 7625583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 216
Study 7625583 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 216
Study 7625583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 2778359 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training sessions and equipment during labor
Number of subjects: 40
Study 31483769 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (TXA)
Number of subjects: 95
Study 31483769 — intervention group
Group type: COMPARATOR
Intervention: Control (non-TXA)
Number of subjects: 95
Study 27811278 — intervention group
Group type: COMPARATOR
Intervention: Oestradiol (oestrogen)
Number of subjects: 40
Study 27811278 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone/Oestradiol combination
Number of subjects: 40
Study 27811278 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 40
Study 27811278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25361769 — intervention group
Group type: EXPERIMENTAL
Intervention: γ-Tocopherol (γ-T) rich mixture of tocopherols (γ-TmT), 500 mg
Number of subjects: 23
Study 25361769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT) with γ-TmT
Number of subjects: 23
Study 25361769 — intervention group
Group type: COMPARATOR
Intervention: Nicotine replacement therapy (NRT) alone (placebo)
Number of subjects: 23
Study 25361769 — intervention group
Group type: EXPERIMENTAL
Intervention: γ-TmT
Number of subjects: 23
Study 25361769 — intervention group
Group type: COMPARATOR
Intervention: NRT-assisted smoking abstinence alone
Number of subjects: 23
Study 23305914 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse talk duration
Number of subjects: 89
Study 23305914 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse characteristics
Number of subjects: 89
Study 22122028 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of co-victimization
Number of subjects: 181
Study 22122028 — intervention group
Group type: EXPERIMENTAL
Intervention: Salience of inclusive social identity
Number of subjects: 181
Study 22122028 — intervention group
Group type: COMPARATOR
Intervention: Co-victimization without inclusive social identity
Number of subjects: 181
Study 19786675 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric Home Hospitalization Service (GHHS)
Number of subjects: 101
Study 19786675 — intervention group
Group type: COMPARATOR
Intervention: General medical ward
Number of subjects: 101
Study 16413892 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.03 mg/kg, remifentanil: propofol (1:500) at 40 microg/kg/min
Number of subjects: 47
Study 16413892 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 0.03 mg/kg, fentanyl 1 microg/kg, propofol at 140 microg/kg/min
Number of subjects: 47
Study 15531170 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral imposed equinus constraint
Number of subjects: 12
Study 12380231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermi-type rabies vaccine (0.25 ml) administered to groups 2-5 of mice for 14 consecutive days.
Number of subjects: 17
Study 12380231 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermi-type rabies vaccine for human PEP (prescribed dosage).
Number of subjects: 17
Study 12380231 — intervention group
Group type: COMPARATOR
Intervention: Phenolized saline (0.25 ml) administered to group 1 of mice for 14 consecutive days.
Number of subjects: 17
Study 9251974 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% sucrose solution
Number of subjects: 60
Study 9251974 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% quinine hydrochloride solution
Number of subjects: 60
Study 9251974 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil
Number of subjects: 60
Study 9251974 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 60
Study 8119426 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival bupivacaine
Number of subjects: 40
Study 8119426 — intervention group
Group type: COMPARATOR
Intervention: Topical amethocaine
Number of subjects: 40
Study 3670697 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Activation Therapy (MAT)
Number of subjects: 30
Study 3670697 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil + Motor Activation Therapy (MAT)
Number of subjects: 30
Study 3670697 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 31159639 — intervention group
Group type: EXPERIMENTAL
Intervention: Distributed practice
Number of subjects: 50
Study 31159639 — intervention group
Group type: COMPARATOR
Intervention: Massed practice
Number of subjects: 50
Study 29338476 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxytherapy (subcutaneous infusion)
Number of subjects: 48
Study 29338476 — intervention group
Group type: COMPARATOR
Intervention: Mesolipolysis using phosphatidylcholine (PPC)
Number of subjects: 48
Study 28449368 — intervention group
Group type: EXPERIMENTAL
Intervention: omarigliptin 25 mg once weekly
Number of subjects: 414
Study 28449368 — intervention group
Group type: EXPERIMENTAL
Intervention: sitagliptin 50 mg once daily
Number of subjects: 414
Study 28449368 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 414
Study 26612980 — intervention group
Group type: EXPERIMENTAL
Intervention: SHRED (multi-ingredient supplement)
Number of subjects: 12
Study 26612980 — intervention group
Group type: COMPARATOR
Intervention: PL (placebo)
Number of subjects: 12
Study 26612980 — intervention group
Group type: EXPERIMENTAL
Intervention: SHRED
Number of subjects: 12
Study 23612106 — intervention group
Group type: EXPERIMENTAL
Intervention: 27.6 mg of iron (ferrous fumarate enriched with 13% haem iron) daily for 12 weeks
Number of subjects: 76
Study 23612106 — intervention group
Group type: COMPARATOR
Intervention: 100 mg ferrosulphate daily for 12 weeks
Number of subjects: 76
Study 21225090 — intervention group
Group type: EXPERIMENTAL
Intervention: NOMAC/E2 (2.5 mg/1.5 mg)
Number of subjects: 90
Study 21225090 — intervention group
Group type: COMPARATOR
Intervention: LNG/EE (100 μg/20 μg)
Number of subjects: 90
Study 21225090 — intervention group
Group type: EXPERIMENTAL
Intervention: NOMAC/E2
Number of subjects: 90
Study 21225090 — intervention group
Group type: COMPARATOR
Intervention: LNG/EE
Number of subjects: 90
Study 18394916 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative concomitant chemo-radiation consisting of 60Gy external-beam radiotherapy and temozolomide (TMZ) administered concomitantly (75mg/m² daily) and after radiotherapy (150-200mg/m², for 5 days every 4 weeks)
Number of subjects: 0
Study 18394916 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrosourea-based chemotherapy or temozolomide re-challenge at time of recurrence/progression
Number of subjects: 0
Study 16460667 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive helping alliance
Number of subjects: 0
Study 16460667 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment expectancy
Number of subjects: 0
Study 16460667 — intervention group
Group type: EXPERIMENTAL
Intervention: High motivation to change
Number of subjects: 0
Study 16460667 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive alliance
Number of subjects: 0
Study 16460667 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the predictors
Number of subjects: 0
Study 12545288 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (over 60 years)
Number of subjects: 69
Study 12545288 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (under 60 years)
Number of subjects: 69
Study 10826576 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted vaginal hysterectomy (LAVH)
Number of subjects: 62
Study 8844442 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily for 15 days (morning administration)
Number of subjects: 16
Study 8844442 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg daily for 15 days (evening administration)
Number of subjects: 16
Study 1321198 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure measurement
Number of subjects: 87
Study 1321198 — intervention group
Group type: COMPARATOR
Intervention: Clinic blood pressure measurement
Number of subjects: 87
Study 1321198 — intervention group
Group type: COMPARATOR
Intervention: Clinic systolic pressure
Number of subjects: 87
Study 1321198 — intervention group
Group type: COMPARATOR
Intervention: Clinic diastolic pressure
Number of subjects: 87
Study 1321198 — intervention group
Group type: COMPARATOR
Intervention: Amplitude of the diurnal profile
Number of subjects: 87
Study 1321198 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean 24-h pressures
Number of subjects: 87
Study 6588486 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (1500 mg infused during 50 minutes)
Number of subjects: 0
Study 6588486 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole (1500 mg infused during 50 minutes)
Number of subjects: 0
Study 29533000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg until disease progression or unacceptable toxicity)
Number of subjects: 160
Study 29533000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib (420 mg)
Number of subjects: 160
Study 29533000 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (up to six cycles)
Number of subjects: 160
Study 27716864 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.6% CHO beverage
Number of subjects: 16
Study 27716864 — intervention group
Group type: COMPARATOR
Intervention: Non-CHO control
Number of subjects: 16
Study 23661492 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg/day
Number of subjects: 160
Study 23661492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular betamethasone
Number of subjects: 160
Study 23661492 — intervention group
Group type: COMPARATOR
Intervention: Control (no alendronate)
Number of subjects: 160
Study 24423369 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow cell (BMC) therapy in non-smokers
Number of subjects: 101
Study 24423369 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow cell (BMC) therapy in smokers
Number of subjects: 101
Study 24423369 — intervention group
Group type: COMPARATOR
Intervention: Active smoking
Number of subjects: 101
Study 20556924 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard formula
Number of subjects: 30
Study 20556924 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula enriched with n-3 fatty acids
Number of subjects: 30
Study 18824999 — intervention group
Group type: EXPERIMENTAL
Intervention: Salzburg Atherosclerosis Prevention Program in Subjects at High Individual Risk study
Number of subjects: 11218
Study 18824999 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexanabinol study
Number of subjects: 11218
Study 16796710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin 2850 IU (0.3 mL)
Number of subjects: 1288
Study 16796710 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin 4000 IU (40 mg)
Number of subjects: 1288
Study 14632678 — intervention group
Group type: EXPERIMENTAL
Intervention: PCM (pantoprazole 40 mg, clarithromycin 500 mg, metronidazole 500 mg)
Number of subjects: 1016
Study 14632678 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA (pantoprazole, clarithromycin, amoxicillin 1000 mg)
Number of subjects: 1016
Study 14632678 — intervention group
Group type: COMPARATOR
Intervention: All regimens tested
Number of subjects: 1016
Study 10863714 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed shortwave diathermy (PSWD) at a constant setting of pulse duration (400 microseconds) and pulse power (190 W) with PRR increased from 26 Hz to 400 Hz in 10 increments, applied for two minutes.
Number of subjects: 30
Study 10863714 — intervention group
Group type: COMPARATOR
Intervention: Placebo group exposed to PSWD at its lowest settings (pulse power = 5 W; pulse duration = 65 microseconds and PRR = 26 Hz).
Number of subjects: 30
Study 9197949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9197949 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 6
Study 9197949 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 6
Study 9197949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1 mg
Number of subjects: 6
Study 9197949 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 6
Study 1283180 — intervention group
Group type: EXPERIMENTAL
Intervention: Acediprol
Number of subjects: 51
Study 1283180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacizine
Number of subjects: 51
Study 3815457 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinaverium bromide (15 mg)
Number of subjects: 10
Study 3815457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30149614 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental opinions on clinical dietary trials
Number of subjects: 17
Study 26204567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 70
Study 26204567 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure Therapy (ET)
Number of subjects: 70
Study 26204567 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 70
Study 24259558 — intervention group
Group type: EXPERIMENTAL
Intervention: High magnesium intake (highest tertile)
Number of subjects: 7216
Study 24259558 — intervention group
Group type: COMPARATOR
Intervention: Control diet (advice on a low-fat diet)
Number of subjects: 7216
Study 24259558 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts or olive oil
Number of subjects: 7216
Study 21414133 — intervention group
Group type: EXPERIMENTAL
Intervention: Flapless implants
Number of subjects: 40
Study 21414133 — intervention group
Group type: COMPARATOR
Intervention: Conventional implants (flap-group)
Number of subjects: 40